Abstract 872P
Background
Intratumor heterogeneity (ITH) is a major cause of treatment failure in cancer. Data on ITH are scarce in head and neck squamous cell carcinoma (HNSCC). We evaluated pathological ITH (pITH) and assessed its prognostic value, along with classical prognostic parameters.
Methods
HNSCC patients treated with curative-intent primary surgery from SCANDARE (NCT03017573) were included. A pITH score (I, II, III-low and III-high) was assessed on biopsies, according to the relative contribution of poorly- and well-differentiated tumor contingents. Univariate and multivariate prognostic Cox models of recurrence-free survival (RFS) were made on pITH score and clinical (age, sex, smoking history, alcohol consumption, AJCC T- and N-stage, HPV status), pathological (differentiation, tumor-infiltrating lymphocytes [TILs], and PD-L1 combined positive score (CPS) features. We tested associations between pITH score and these parameters.
Results
A total of 88 patients were included. Most frequently tumor locations were oral cavity (51%). Most patients had low T-stage (T1-2, 59%) and HPV-negative tumor (74%). Ten patients (11%) had a I/II ITH score, 49 (56%) a III-low and 29 (33%) a III-high. Median follow-up was 17 months and median RFS was 18 months (95% CI, 14-40). In univariate analysis, the pITH score did not correlate with RFS (P = 0.6). T-stage, N-stage and TILs enrichment were associated with RFS (T3-4 vs T1-2, HR = 2.7, 95% CI, 1.4-5.3; N1-2 vs N0, HR = 1.9, 95% CI, 1.0-3.7; TILs ≥10% vs TILs <10%, HR = 0.3, 95% CI, 0.1-0.8). We found that low T-stage (T1-2) and high TILs enrichment (TILs ≥10%) were associated with a reduced risk of relapse in multivariate analysis (HR = 0.4, 95% CI, 0.2-0.9 and HR = 0.2, 95% CI, 0.04-0.5, respectively). In comparison with non-smokers, smokers had a higher proportion of tumors with I-II ITH score (19% vs 3%) and a lower proportion of tumors with III-low ITH score (48% vs 65%, adjusted P = 0.05).
Conclusions
We reported an association between pITH score and smoking history. pITH score was not found to be prognostic whereas TILs enrichment ≥10% was associated with a favorable prognosis in patients with HNSCC treated with upfront surgery. This finding is to be confirmed in an independent population.
Clinical trial identification
NCT03017573 SCANDARE.
Editorial acknowledgement
Legal entity responsible for the study
Pr Christophe Le Tourneau.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
890P - Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Nabil Saba
Session: Poster session 12
891P - Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 12
892P - Real-world data validation of university of San Diego nomogram for the prediction of benefit of intensive treatment for locoregionally advanced head and neck cancer
Presenter: Javier Caballero Daroqui
Session: Poster session 12
893P - Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma
Presenter: Jozsef Timar
Session: Poster session 12
894P - Is pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real-world data study of 900 plus patients
Presenter: Shatabdi Chakraborty
Session: Poster session 12
896P - Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
Presenter: Kai Wang
Session: Poster session 12
897P - Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Presenter: Darshit Shah
Session: Poster session 12
898P - Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head & neck cancer (LAHNC)
Presenter: Neal Dunlap
Session: Poster session 12
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12